Latest Clinical Trials
NORD and other rare disease organizations around the world will celebrate Rare Disease Day on February 28, 2022, with most events being held virtually.
Dr. Haggi Mazeh, chief of surgery at one of Israel’s top hospitals, discusses diagnosing and treating medullary thyroid carcinoma.
MTC “can get aggressive and nasty” but it is not necessarily a death sentence, said surgical oncologist David Goldenberg, MD, FACS, author of a new book.
One question that will arise for most if not every patient, is the question of prognosis. Whenever I did bring up that question, I never received an answer.
Being diagnosed with medullary thyroid carcinoma (MTC) likely means one loses his or her thyroid.
As a 25-year-old young adult receiving a cancer diagnosis, starting a family had still been a dream, one that became very uncertain if not obsolete.
MTC Clinical Insights
We look at how our understanding of medullary thyroid carcinoma has evolved over the last several decades, and what we now know about treating the cancer.
We take a look at epidemiological data on the global distribution of RET mutations in cases of medullary thyroid carcinoma.
We examine the lasting impact of innovative clinical trial designs for rare diseases on other clinical experiments.
We discuss the case study of a patient who was diagnosed with medullary thyroid carcinoma with paraneoplastic Cushing‘s syndrome.
We discuss current therapeutic strategies in targeting the PDGF/PDGFR signaling pathway in cancer research.
Rare Care Podcast
Endocrine Surgeon Dr. Haggi Mazeh Describes the Challenges of Treating MTC